| Morphology . | n = 129 . |
|---|---|
| Sample thickness, mm | 2.73 ± 1.28 |
| Sample area, mm2 | 11.95 (7.15–29.90) |
| Endocardium inclusion | 114 (88.4%) |
| Cardiomyocyte diameter, μma | 36.38 ± 7.12 |
| Endocardium thicknessb, μm | 134.0 (76.5–205.7) |
| Elastic depositionc | 114 (88.4%) |
| Elastic/endocardium ratio | 0.38 ± 0.18 |
| Disarrayd | 20 (15.5%) |
| Vascular abnormalitiese | 79 (61.2%) |
| Perivascular fibrosis | 123 (95.3%) |
| Replacement fibrosisf | 41 (31.8%) |
| Quantification of fibrosis, % | 11.90 (6.54–19.97) |
| Cardiomyocyte ischaemic like changes | 58 (45%) |
| Immunohistochemistryg | n = 129 |
| Alpha-actin | 89 (69%) |
| CD45+ | 107 (82.9%) |
| CD45+/fieldh | 3.0 (1.1–6.0) |
| CD3+ | 102 (79.1%) |
| CD20+ | 7 (5.4%) |
| CD68+ | 68 (47.3%) |
| Immunohistochemistry for collagen type and ECM remodelling, n = 60 | |
| Perivascular Type I collagen | 60 (100%) |
| Tenascin C | 15 (25.0%) |
| Fibronectin | 49 (81.7%) |
| Morphology . | n = 129 . |
|---|---|
| Sample thickness, mm | 2.73 ± 1.28 |
| Sample area, mm2 | 11.95 (7.15–29.90) |
| Endocardium inclusion | 114 (88.4%) |
| Cardiomyocyte diameter, μma | 36.38 ± 7.12 |
| Endocardium thicknessb, μm | 134.0 (76.5–205.7) |
| Elastic depositionc | 114 (88.4%) |
| Elastic/endocardium ratio | 0.38 ± 0.18 |
| Disarrayd | 20 (15.5%) |
| Vascular abnormalitiese | 79 (61.2%) |
| Perivascular fibrosis | 123 (95.3%) |
| Replacement fibrosisf | 41 (31.8%) |
| Quantification of fibrosis, % | 11.90 (6.54–19.97) |
| Cardiomyocyte ischaemic like changes | 58 (45%) |
| Immunohistochemistryg | n = 129 |
| Alpha-actin | 89 (69%) |
| CD45+ | 107 (82.9%) |
| CD45+/fieldh | 3.0 (1.1–6.0) |
| CD3+ | 102 (79.1%) |
| CD20+ | 7 (5.4%) |
| CD68+ | 68 (47.3%) |
| Immunohistochemistry for collagen type and ECM remodelling, n = 60 | |
| Perivascular Type I collagen | 60 (100%) |
| Tenascin C | 15 (25.0%) |
| Fibronectin | 49 (81.7%) |
Values are median (interquartile range), mean ± standard deviation.
aTransversal measurement performed at the centre cell plane (cross-section encompassing the nucleus at haematoxylin–eosin × 40).
bAs the mean of 5–10 measurements.
cIdentified at elastic van Gieson’s stain.
dConsidered when in the presence of cellular interlacing, whirling, or herringbone architecture arrangement.
eConsidered for abnormal vessel walls (intimal and medial smooth muscle cell hyperplasia; luminal distortion and narrowing).
fDefined for large coalescent areas of fibrosis.
gCaspase-3 was un-interpretable; CD90 had inconsistent ground noise positivity and was also considered un-interpretable.
hNumber of positive cells per ×20 amplification field of view.
| Morphology . | n = 129 . |
|---|---|
| Sample thickness, mm | 2.73 ± 1.28 |
| Sample area, mm2 | 11.95 (7.15–29.90) |
| Endocardium inclusion | 114 (88.4%) |
| Cardiomyocyte diameter, μma | 36.38 ± 7.12 |
| Endocardium thicknessb, μm | 134.0 (76.5–205.7) |
| Elastic depositionc | 114 (88.4%) |
| Elastic/endocardium ratio | 0.38 ± 0.18 |
| Disarrayd | 20 (15.5%) |
| Vascular abnormalitiese | 79 (61.2%) |
| Perivascular fibrosis | 123 (95.3%) |
| Replacement fibrosisf | 41 (31.8%) |
| Quantification of fibrosis, % | 11.90 (6.54–19.97) |
| Cardiomyocyte ischaemic like changes | 58 (45%) |
| Immunohistochemistryg | n = 129 |
| Alpha-actin | 89 (69%) |
| CD45+ | 107 (82.9%) |
| CD45+/fieldh | 3.0 (1.1–6.0) |
| CD3+ | 102 (79.1%) |
| CD20+ | 7 (5.4%) |
| CD68+ | 68 (47.3%) |
| Immunohistochemistry for collagen type and ECM remodelling, n = 60 | |
| Perivascular Type I collagen | 60 (100%) |
| Tenascin C | 15 (25.0%) |
| Fibronectin | 49 (81.7%) |
| Morphology . | n = 129 . |
|---|---|
| Sample thickness, mm | 2.73 ± 1.28 |
| Sample area, mm2 | 11.95 (7.15–29.90) |
| Endocardium inclusion | 114 (88.4%) |
| Cardiomyocyte diameter, μma | 36.38 ± 7.12 |
| Endocardium thicknessb, μm | 134.0 (76.5–205.7) |
| Elastic depositionc | 114 (88.4%) |
| Elastic/endocardium ratio | 0.38 ± 0.18 |
| Disarrayd | 20 (15.5%) |
| Vascular abnormalitiese | 79 (61.2%) |
| Perivascular fibrosis | 123 (95.3%) |
| Replacement fibrosisf | 41 (31.8%) |
| Quantification of fibrosis, % | 11.90 (6.54–19.97) |
| Cardiomyocyte ischaemic like changes | 58 (45%) |
| Immunohistochemistryg | n = 129 |
| Alpha-actin | 89 (69%) |
| CD45+ | 107 (82.9%) |
| CD45+/fieldh | 3.0 (1.1–6.0) |
| CD3+ | 102 (79.1%) |
| CD20+ | 7 (5.4%) |
| CD68+ | 68 (47.3%) |
| Immunohistochemistry for collagen type and ECM remodelling, n = 60 | |
| Perivascular Type I collagen | 60 (100%) |
| Tenascin C | 15 (25.0%) |
| Fibronectin | 49 (81.7%) |
Values are median (interquartile range), mean ± standard deviation.
aTransversal measurement performed at the centre cell plane (cross-section encompassing the nucleus at haematoxylin–eosin × 40).
bAs the mean of 5–10 measurements.
cIdentified at elastic van Gieson’s stain.
dConsidered when in the presence of cellular interlacing, whirling, or herringbone architecture arrangement.
eConsidered for abnormal vessel walls (intimal and medial smooth muscle cell hyperplasia; luminal distortion and narrowing).
fDefined for large coalescent areas of fibrosis.
gCaspase-3 was un-interpretable; CD90 had inconsistent ground noise positivity and was also considered un-interpretable.
hNumber of positive cells per ×20 amplification field of view.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
